Network pharmacology-based study on the mechanism of ShenKang injection in diabetic kidney disease through Keap1/Nrf2/Ho-1 signaling pathway

•SKI can improve the general symptoms of DKD rats, reduce 24 h proteinuria, protect rat kidney function, reduce blood lipids and reduce oxidative stress.•SKI drug-containing serum can reduce excessive oxidative stress damage of HK-2 cells induced by AGEs in vitro experiments.•The molecular mechanism...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Phytomedicine (Stuttgart) 2023-09, Vol.118, p.154915-154915, Article 154915
Hauptverfasser: Liu, Yunhua, Wang, Sitong, Jin, Ge, Gao, Kun, Wang, Shuyue, Zhang, Xinjiang, Zhou, Kaidong, Cai, Yanmo, Zhou, Xin, Zhao, Zongjiang
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•SKI can improve the general symptoms of DKD rats, reduce 24 h proteinuria, protect rat kidney function, reduce blood lipids and reduce oxidative stress.•SKI drug-containing serum can reduce excessive oxidative stress damage of HK-2 cells induced by AGEs in vitro experiments.•The molecular mechanism of SKI to protect kidney function in rats may be achieved by regulating the Keap1/Nrf2/Ho-1 signaling pathway.•SKI may achieve the effect of preventing DKD by affecting 118 potential targets. To study the effect of ShenKang Injection (SKI) on the kidneys of DKD rats and its effect on oxidative stress mediated by the Keap1/Nrf2/Ho-1 signaling pathway through network pharmacology and in vivo and in vitro experiments. SKI drug targets were screened by TCMSP, DKD targets were screened by GenGards, OMIM, Drugbank, TTD, and Disgenet databases, and the two intersected for PPI network analysis and target prediction was performed by GO and KEGG. A total of 40 SD rats were randomly divided into 10 in the control group and 30 in the model group. After the model group was fed 8 W with high-sugar and high-fat diets, a DKD model was constructed by one-time intraperitoneal injection of streptozotocin (35 mg/kg). According to the weight, the model animals were randomly divided into three groups: 8 for model validation group, 8 for Irbesartan (25 mg/kg daily) group, and 8 for SKI group (5 ml/kg). Gavaged deionized water was given to the control group and the model validation group equally. The general conditions of the rats were observed, their body weights measured and their urine volumes recorded for 24 h. After the intervention of 16 W, serum was collected to detect Urea, Scr, blood lipids, and oxidative stress and lipid peroxidation indicators; Transmission electron microscopy, HE and Mallory staining were used to observe the pathological morphology of renal tissue. Immunohistochemistry and RT-PCR were used to detect the expression of Keap1, Nrf2, Ho-1, Gpx4 proteins and mRNA in rat kidney tissues. HK-2 cells were cultured in vitro and divided into: the control group, AGEs (200 μg/ml) group and AGEs + SKI group. The cell activity of the groups was detected using CCK-8 after 48 h of cell culture, and ROS were detected using fluorescent probes. Gpx4 expression was detected by immunofluorescence, while Keap1, Nrf2, Ho-1, and Gpx4 were detected by Western Blot. Network pharmacological analysis predicted that SKI may delay DKD kidney injury by affecting redox-related signaling p
ISSN:0944-7113
1618-095X
DOI:10.1016/j.phymed.2023.154915